ANI Pharmaceuticals (ANIP) has an average rating of outperform and price targets ranging from $40 to $55, according to analysts polled by Capital IQ. (MT...
ANI Pharmaceuticals (ANIP) reported Q4 adjusted earnings early Thursday of $0.76 per diluted share, up from $0.06 a year earlier. Analysts polled by...
...
...
| Address | 210 Main Street West Baudette, Minnesota 56623 |
| Phone | +1.218.634.3500 |
| Number of Employees | 299 |
| Recent SEC Filing | 03/10/2023 8-K |
| President, Chief Executive Officer & Director | Nikhil Lalwani |
| Senior VP-Operations & Product Development | James G. Marken |
| Chief Financial Officer & Senior VP-Finance | Stephen P. Carey |
| Director & Head-Research & Development | Muthusamy Shanmugam |
| Price Open | $37.49 |
| Previous Close | $37.82 |
| 52 Week Range | $22.31 - 45.99 |
| Market Capitalization | $657.9 M |
| Shares Outstanding | 17.5 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 05/09/2023 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.54 |
| Beta vs. S&P 500 | N/A |
| Revenue | $201.6 M |
| Net Profit Margin | -15.14% |
| Return on Equity | -14.11% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
